Denver, CO, March 12, 2018 (GLOBE NEWSWIRE) --
FutureLand Corp. (OTC: FUTL), a leading provider of strategic real estate investment, grow facilities and material solutions to the medical and recreational global cannabis industry, announced today that Apotheca Biosciences was bought by Cannabis Leaf (PCFP) through a merger agreement. FutureLand Corp. has 20% interest in Apotheca Biosciences.
Cameron Cox, CEO of FutureLand Corp. said, "We always saw great value in Apotheca Biosciences. CBD and the benefits for the pharmacological community are far reaching and gaining ground every day.”
FutureLand Corp. (FUTL) purchased 20% of Apotheca Biosciences on Sept. 15, 2017 for a $100,000 note. Today the company announces that Apotheca Biosciences has been purchased by Cannabis Leaf (PCFP) through a merger agreement. FutureLand Corp. will receive 12,000,000 shares of newly issued (PCFP) common stock for its interest in Apotheca Biosciences.
With soaring market caps in the space, FutureLand Corp. is a big winner in the acquisition. It marks a turning point for the company’s fiscal health. FutureLand expects major growth for Cannabis Leaf via this transaction and plans on taking a long-term hold position in the company.
Apotheca Biosciences is developing cutting-edge medical products, nutraceuticals, formulation and delivery technologies for the healthcare and consumer care industry. They have a pipeline of products that include, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. We believe that they can deliver meaningful benefits using their technologies to the world’s aging population.
Further, Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of their customers takes precedence and their solid business strategy ensures their focus on customer well-being. Their goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects their research.
FutureLand Corp. is pleased with the investment and looks forward to great things to come from Apotheca Biosciences.
About FutureLand Corp.
FutureLand Corp., a Colorado company, is a cannabis and hemp specialty zoned land leasing company formed to capitalize upon the emerging global cannabis market. FutureLand, focuses on target acquisition, zoning, license fulfillment, site plan preparation and financing of cannabis or hemp grow facilities throughout the United States. We give growers the opportunity to grow. We monetize through leasing the land, leasing the structures on the land, financing interest revenue and management fees associated with cultivation centers. FutureLand retains ownership of all the land and the structures. FutureLand leases to both medical marijuana, retail marijuana as well as industrial hemp growers. FutureLand does not currently grow, distribute or sell marijuana. To request further information about FutureLand, please email us at firstname.lastname@example.org, log onto our website at http://www.futurelandcorp.com, or visit us on FB @ futurelandcorp and Twitter @futurelandcorp.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.